Cell surface markers for immunophenotyping human pluripotent stem cell-derived cardiomyocytes

被引:0
作者
Kenneth R. Boheler
Ellen Ngar-Yun Poon
机构
[1] The Johns Hopkins University,Department of Biomedical Engineering
[2] The Chinese University of Hong Kong,Department, of Medicine and Therapeutics, Centre for Cardiovascular Genomics and Medicine, Lui Che Woo Institute of Innovative Medicine
[3] Hong Kong Hub of Paediatric Excellence,undefined
[4] The Chinese University of Hong Kong,undefined
来源
Pflügers Archiv - European Journal of Physiology | 2021年 / 473卷
关键词
Human pluripotent stem cells; Cardiomyocytes; Cell surface marker; Heterogeneity; Maturation; Cardiac marker;
D O I
暂无
中图分类号
学科分类号
摘要
Human pluripotent stem cells (hPSC) self-renew and represent a potentially unlimited source for the production of cardiomyocytes (CMs) suitable for studies of human cardiac development, drug discovery, cardiotoxicity testing, and disease modelling and for cell-based therapies. However, most cardiac differentiation protocols yield mixed cultures of atrial-, ventricular-, and pacemaker-like cells at various stages of development, as well as non-CMs. The proportions and maturation states of these cell types result from disparities among differentiation protocols and time of cultivation, as well as hPSC reprogramming inconsistencies and genetic background variations. The reproducible use of hPSC-CMs for research and therapy is therefore limited by issues of cell population heterogeneity and functional states of maturation. A validated method that overcomes issues of cell heterogeneity is immunophenotyping coupled with live cell sorting, an approach that relies on accessible surface markers restricted to the desired cell type(s). Here we review current progress in unravelling heterogeneity in hPSC-cardiac cultures and in the identification of surface markers suitable for defining cardiac identity, subtype specificity, and maturation states.
引用
收藏
页码:1023 / 1039
页数:16
相关论文
共 1114 条
[1]  
Ahmed RE(2020)A brief review of current maturation methods for human induced pluripotent stem cells-derived cardiomyocytes Front Cell Dev Biol 8 178-2077
[2]  
Anzai T(2017)Current strategies and challenges for purification of cardiomyocytes derived from human pluripotent stem cells Theranostics 7 2067-1249
[3]  
Chanthra N(2015)Non-genetic purification of ventricular cardiomyocytes from differentiating embryonic stem cells through molecular beacons targeting IRX-4 Stem cell reports 5 1239-1909
[4]  
Uosaki H(2013)Purification of cardiomyocytes from differentiating pluripotent stem cells using molecular beacons that target cardiomyocyte-specific mRNA Circulation 128 1897-2310
[5]  
Ban K(2015)A mass spectrometric-derived cell surface protein atlas PLoS ONE 10 e0121314-740
[6]  
Bae S(2008)Control of human embryonic stem cell colony and aggregate size heterogeneity influences differentiation trajectories Stem Cells 26 2300-29
[7]  
Yoon YS(2014)Chemical ablation of tumor-initiating human pluripotent stem cells Nat Protoc 9 729-745
[8]  
Ban K(2014)High efficiency differentiation of human pluripotent stem cells to cardiomyocytes and characterization by flow cytometry J V Exp 91 52010-203
[9]  
Wile B(2020)Addressing variability and heterogeneity of induced pluripotent stem cell-derived cardiomyocytes Adv Exp Med Biol 1212 1-138
[10]  
Cho KW(2015)Contractile defect caused by mutation in MYBPC3 revealed under conditions optimized for human PSC-cardiomyocyte function Cell Rep 13 733-21.3.15